X

Trial Profile

A phase I study of BI-1808 with and without anti-PD1 antibody in patients with solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI 1808 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

31 Oct 2023 According to a BioInvent International media release, latest data from the other Treg program, i.e. the BI-1808 single agent Phase 1 study, will be presented at SITC on November 3, 2023.
22 Jun 2020 According to a BioInvent International media release, this trial is expected to start before the end of 2020.
26 Feb 2020 According to a BioInvent International media release, a clinical trialapplication is expected to be submitted in H1 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com